Bexion Pharmaceuticals

Bexion Pharmaceuticals, headquartered at 632 Russell Street, Covington, KY 41011, is a mid-stage clinical company dedicated to developing transformative treatments in the fields of Oncology and Central Nervous System (CNS) disorders. The company’s lead compound, BXQ-350, is a novel S1P modulator that has demonstrated significant activity in oncology and CNS applications. BXQ-350 selectively targets tumor cells due to its component Saposin C’s strong affinity for phosphatidylserine, and its mechanisms of action include S1P reduction properties, modulation of the tumor microenvironment, and elevation of ceramide programmed cell death. This compound has shown potential in treating metastatic colorectal cancer (mCRC), malignant glioma, including diffuse intrinsic pontine glioma (DIPG), and chemotherapy-induced peripheral neuropathy (CIPN), with evidence of anti-tumor activity and a tolerable safety profile with no dose-limiting toxicity at the highest administered dose. Bexion Pharmaceuticals has received Orphan Drug status for BXQ-350 for the treatment of malignant glioma, which offers benefits such as research grant eligibility, potential tax credits, waiver of FDA application user fees, and potentially faster regulatory processes. The company is committed to pediatric cancer therapies, including DIPG and diffuse midline glioma (DMG), and collaborates with patient advocacy organizations to align its priorities with those of patients and their families. Bexion Pharmaceuticals has completed enrollment in Phase 1 studies in both adults and children with advanced solid tumors using BXQ-350 as monotherapy and continues to progress its pipeline to develop life-changing oncology therapies.